Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:15PM ET
38.50
Dollar change
-0.15
Percentage change
-0.39
%
IndexRUT P/E- EPS (ttm)-0.69 Insider Own28.22% Shs Outstand60.35M Perf Week-7.45%
Market Cap2.52B Forward P/E- EPS next Y-1.92 Insider Trans-16.24% Shs Float47.05M Perf Month10.25%
Income-32.18M PEG- EPS next Q-0.42 Inst Own68.34% Short Float11.93% Perf Quarter93.27%
Sales58.88M P/S42.86 EPS this Y-170.51% Inst Trans37.61% Short Ratio4.98 Perf Half Y229.06%
Book/sh5.43 P/B7.08 EPS next Y-10.83% ROA-9.63% Short Interest5.61M Perf Year433.24%
Cash/sh4.99 P/C7.71 EPS next 5Y- ROE-12.69% 52W Range6.71 - 42.88 Perf YTD101.99%
Dividend Est.- P/FCF- EPS past 5Y24.56% ROI-9.55% 52W High-10.21% Beta1.13
Dividend TTM- Quick Ratio7.86 Sales past 5Y171.70% Gross Margin99.02% 52W Low473.77% ATR (14)2.12
Dividend Ex-Date- Current Ratio7.86 EPS Y/Y TTM58.73% Oper. Margin-75.16% RSI (14)59.26 Volatility6.28% 5.71%
Employees142 Debt/Eq0.03 Sales Y/Y TTM95.84% Profit Margin-54.66% Recom1.00 Target Price45.00
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q124.03% Payout- Rel Volume0.24 Prev Close38.65
Sales Surprise238.91% EPS Surprise145.45% Sales Q/Q1011.42% EarningsMar 18 AMC Avg Volume1.13M Price38.50
SMA202.97% SMA5022.79% SMA200115.96% Trades Volume120,956 Change-0.39%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated Wolfe Research Outperform $44
Oct-18-23Initiated Berenberg Buy $18
Oct-17-23Initiated Berenberg Buy $18
Oct-05-23Initiated RBC Capital Mkts Outperform $19
Jun-26-23Resumed Oppenheimer Outperform $14
Jan-19-23Initiated Morgan Stanley Overweight $17
Nov-21-22Initiated SVB Leerink Outperform $15
Dec-21-20Initiated H.C. Wainwright Buy $21
Aug-26-20Initiated Cowen Outperform
Mar-21-24 07:45AM
Mar-20-24 04:30PM
Mar-19-24 08:32AM
06:48AM
Mar-18-24 08:53PM
07:25PM Loading…
07:25PM
05:31PM
04:05PM
Mar-14-24 08:38AM
Mar-11-24 10:00AM
Mar-07-24 04:30PM
Feb-26-24 04:30PM
Feb-01-24 04:30PM
Dec-21-23 04:15PM
Dec-19-23 09:50AM
04:30PM Loading…
Dec-18-23 04:30PM
Dec-06-23 09:55AM
Nov-29-23 09:40AM
Nov-20-23 04:30PM
09:55AM
Nov-17-23 07:44PM
Nov-15-23 09:00AM
Nov-14-23 08:55PM
04:15PM
03:57PM
Nov-13-23 09:00AM
Nov-06-23 09:41PM
06:00AM
Nov-03-23 09:00AM
Nov-02-23 09:00AM
10:01AM Loading…
Oct-30-23 10:01AM
09:00AM
Oct-27-23 09:40AM
Oct-23-23 12:00PM
Oct-13-23 09:05AM
Oct-12-23 12:13PM
Oct-11-23 10:15AM
Oct-09-23 11:10AM
Oct-06-23 09:55AM
09:24AM
Oct-04-23 08:17AM
08:00AM
Oct-03-23 07:43AM
Sep-18-23 08:52AM
Sep-12-23 08:30AM
Sep-08-23 09:40AM
Sep-05-23 04:30PM
08:30AM
Aug-30-23 04:30PM
Aug-24-23 08:50AM
Aug-22-23 04:30PM
Aug-17-23 09:55AM
Aug-14-23 04:15PM
Jul-23-23 10:25AM
Jun-22-23 07:43AM
Jun-20-23 07:14PM
May-19-23 04:30PM
May-11-23 04:15PM
May-05-23 07:04AM
May-01-23 04:30PM
Mar-27-23 09:16AM
07:08AM
Mar-24-23 10:02AM
Mar-23-23 05:35PM
04:05PM
Mar-20-23 04:30PM
Mar-16-23 05:30PM
Mar-15-23 04:30PM
Feb-28-23 04:33PM
Feb-13-23 05:16AM
Feb-09-23 04:45PM
Jan-17-23 08:36AM
Nov-22-22 04:15PM
Nov-16-22 05:58AM
Nov-14-22 05:25PM
04:05PM
Nov-07-22 04:30PM
Nov-04-22 04:46AM
Nov-03-22 04:15PM
09:00AM
Nov-02-22 10:01AM
Oct-26-22 04:30PM
Oct-25-22 01:04AM
Oct-24-22 10:33AM
07:30AM
Oct-18-22 08:01AM
Oct-12-22 08:22AM
Sep-26-22 08:00AM
Sep-22-22 04:06PM
Sep-20-22 11:26PM
04:15PM
Sep-12-22 04:05PM
Sep-06-22 04:05PM
Sep-04-22 09:11AM
Aug-30-22 04:05PM
Aug-18-22 04:05PM
Aug-15-22 12:00PM
Aug-14-22 08:57AM
Aug-11-22 04:05PM
Aug-10-22 07:54AM
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which focusses on discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rickey James PaulSee RemarksJan 26 '24Option Exercise8.30117,764977,84473,764Jan 29 07:04 PM
Rickey James PaulSee RemarksJan 26 '24Sale23.32117,7642,745,8300Jan 29 07:04 PM
Rickey James PaulSee RemarksJan 25 '24Option Exercise6.512361,536236Jan 29 07:04 PM
Rickey James PaulSee RemarksJan 25 '24Sale22.002365,1920Jan 29 07:04 PM
GOLD MITCHELLExecutive Chairman and CEODec 28 '23Option Exercise12.7474,441948,3782,675,421Dec 29 07:32 PM
GOLD MITCHELLExecutive Chairman and CEODec 28 '23Option Exercise0.651,0166601,016Dec 29 07:32 PM
ORBIMED ADVISORS LLCDirectorDec 28 '23Sale18.351,364,84925,049,034264,315Dec 29 04:18 PM
Thompson Peter A.DirectorDec 28 '23Sale18.351,364,84925,049,034264,315Dec 29 04:20 PM
GOLD MITCHELLExecutive Chairman and CEODec 28 '23Sale20.041,01620,3620Dec 29 07:32 PM
GOLD MITCHELLExecutive Chairman and CEODec 27 '23Option Exercise0.6529,57319,22229,573Dec 27 09:07 PM
ORBIMED ADVISORS LLCDirectorDec 27 '23Sale19.96181,4983,622,700406,609Dec 29 04:18 PM
Thompson Peter A.DirectorDec 27 '23Sale19.96181,4983,622,700406,609Dec 29 04:20 PM
GOLD MITCHELLExecutive Chairman and CEODec 27 '23Sale20.0429,573592,7170Dec 27 09:07 PM
GOLD MITCHELLExecutive Chairman and CEODec 26 '23Option Exercise0.6324,48615,43624,486Dec 27 09:07 PM
GOLD MITCHELLExecutive Chairman and CEODec 26 '23Sale20.2224,486495,2170Dec 27 09:07 PM
GOLD MITCHELLExecutive Chairman and CEODec 22 '23Option Exercise0.4537,82517,02137,825Dec 27 09:07 PM
GOLD MITCHELLExecutive Chairman and CEODec 22 '23Sale20.4337,825772,5950Dec 27 09:07 PM
Rickey James PaulSee RemarksDec 19 '23Option Exercise5.0215,21376,36915,213Dec 21 07:35 PM
GOLD MITCHELLExecutive Chairman and CEODec 19 '23Option Exercise0.452,4021,0812,402Dec 21 07:34 PM
Rickey James PaulSee RemarksDec 19 '23Sale19.2115,213292,2220Dec 21 07:35 PM
GOLD MITCHELLExecutive Chairman and CEODec 19 '23Sale20.012,40248,0640Dec 21 07:34 PM
Rickey James PaulSee RemarksDec 18 '23Option Exercise5.021,8009,0361,800Dec 18 09:20 PM
Rickey James PaulSee RemarksDec 18 '23Sale19.001,80034,2030Dec 18 09:20 PM
Rickey James PaulSee RemarksDec 15 '23Option Exercise5.0245,387227,84345,387Dec 18 09:20 PM
Rickey James PaulSee RemarksDec 15 '23Sale19.0945,387866,3830Dec 18 09:20 PM
Rickey James PaulSee RemarksDec 14 '23Option Exercise5.0211,60058,23211,600Dec 18 09:20 PM
Rickey James PaulSee RemarksDec 14 '23Sale19.0011,600220,4060Dec 18 09:20 PM
GOLD MITCHELLExecutive Chairman and CEODec 12 '23Option Exercise0.458,6133,8768,613Dec 12 09:02 PM
GOLD MITCHELLExecutive Chairman and CEODec 12 '23Sale17.3241,063711,0260Dec 12 09:02 PM
GOLD MITCHELLExecutive Chairman and CEODec 11 '23Sale17.2668,8701,189,02732,450Dec 12 09:02 PM
GOLD MITCHELLExecutive Chairman and CEODec 08 '23Sale17.088,067137,784101,320Dec 12 09:02 PM
Rickey James PaulSee RemarksDec 06 '23Option Exercise3.236,44620,8216,446Dec 06 07:31 PM
Rickey James PaulSee RemarksDec 06 '23Sale16.086,446103,6500Dec 06 07:31 PM
Rickey James PaulSee RemarksDec 05 '23Option Exercise3.234181,350418Dec 06 07:31 PM
Rickey James PaulSee RemarksDec 05 '23Sale16.014186,6940Dec 06 07:31 PM
Rickey James PaulSee RemarksDec 04 '23Option Exercise3.2363,947206,54963,947Dec 06 07:31 PM
Rickey James PaulSee RemarksDec 04 '23Sale16.0663,9471,026,8870Dec 06 07:31 PM
Rickey James PaulSee RemarksNov 30 '23Option Exercise3.237002,261700Dec 01 05:00 PM
Rickey James PaulSee RemarksNov 30 '23Sale16.0070011,2000Dec 01 05:00 PM
Rickey James PaulSee RemarksNov 06 '23Option Exercise3.2310,98935,49418,003Nov 08 05:20 PM
Rickey James PaulSee RemarksNov 06 '23Sale16.0318,003288,5540Nov 08 05:20 PM